Abstract
BackgroundCabotegravir/rilpivirine (CAB/RPV) is the first long-acting injectable (LAI) antiretroviral therapy (ART) approved for virologically suppressed adults with HIV-1. While clinical trials have provided safety and efficacy data for this new...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
